Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

Published 2017 View Full Article

Authors

Keywords

Journal

Cancer Discovery

Volume 7, Issue 6, Pages 620-629

Publisher

American Association for Cancer Research (AACR)

Online

2017-02-28

DOI

10.1158/2159-8290.cd-16-1250

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

Cancer Discovery

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Ask a Question. Answer a Question.